Maximizing Therapeutic Safety and Efficacy in IBD: A Treat-to-Target Approach

Dr. Miguel Regueiro earned his bachelor’s degree at the University of Pennsylvania and his medical degree at Hahnemann University in Philadelphia, Pennsylvania. He completed his internal medicine internship and residency and his clinical and research fellowship training in gastroenterology at Harvard Medical School’s Beth Israel Hospital in Boston, Massachusetts.

 

Dr. Regueiro is professor of medicine at the University of Pittsburgh School of Medicine, head of the Clinical Inflammatory Bowel Disease Program, and co-director of the Inflammatory Bowel Disease Center at the University of Pittsburgh Medical Center. He is also the associate chief for education and former director of the Gastroenterology, Hepatology, and Nutrition Fellowship Training Program at the University of Pittsburgh.

 

Dr. Regueiro’s main clinical and research interest is inflammatory bowel disease (IBD), with a focus on Crohn’s disease and ulcerative colitis. He has published extensively on the prevention and management of postoperative Crohn’s disease and genotype-phenotype correlations in IBD. He is the principal investigator on several multi-center, international research trials and conducts clinical research that defines the natural course and phenotypes of IBD. Dr. Regueiro has developed a multidisciplinary IBD center that operates as a state-of-the-art clinic for patients with Crohn’s disease and ulcerative colitis.

 

Dr. Regueiro has received several honors and holds membership in professional and scientific societies, including the Alpha Omega Alpha Honor Medical Society, the Joan Komblum Memorial Prize for Excellence in Internal Medicine, the Clinical Investigator Training Award from Harvard/MIT Health Sciences, the Crohn’s & Colitis Foundation of America (CCFA) Physician of the Year, the National Research Excellence in GI disease award, numerous fellowship teaching awards, and American Gastroenterological Association and American College of Gastroenterology Fellowships. He is also a member and fellow of the American Gastroenterological Association, the American College of Gastroenterology, and the American College of Physicians. He is a member of CCFA and co-chair of CCFA’s professional education committee. In addition, Dr. Regueiro has been an invited lecturer and keynote speaker for national and international seminars and has published many articles, reviews, and abstracts in peer-reviewed gastroenterology journals.

Dr. Gil Y. Melmed received his medical degree from Albert Einstein College of Medicine in New York, New York. He completed his residency at Cedars-Sinai Medical Center in Los Angeles, California, and his gastroenterology fellowship at University of California, Los Angeles, where he also received a master's of science in clinical research. He is board certified by the American Board of Internal Medicine in gastroenterology.

 

Dr. Melmed is director of clinical trials at the Clinical Inflammatory Bowel Disease (IBD) Center at Cedars-Sinai Medical Center and associate professor of medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). His main clinical and research interests are clinical outcomes in IBD (Crohn’s disease and ulcerative colitis), including health-related quality of life, post-operative outcomes, vaccination and health maintenance issues in patients with IBD, and quality of care for IBD. He has authored or co-authored over 70 publications and serves as a review editor for Inflammatory Bowel Disease. He is an active member of the Crohn’s & Colitis Foundation of America and co-chair of the national Quality of Care Committee.